Salivary 17 α-hydroxyprogesterone ELISA Kit

Name: Salivary 17 α-hydroxyprogesterone ELISA Kit
SKU: DEIA-S10023
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

saliva

Species Reactivity

Human

Detection Method

Competitive ELISA

Intended Use

The Salimetrics salivary 17 α-hydroxyprogesterone (17OHP) kit is a competitive immunoassay specifically designed and validated for the quantitative measurement of salivary 17OHP. It is not intended for diagnostic use. It is intended only for research use in humans and some animals. Please read the complete kit insert before performing this assay. For further information about this kit, its applications, or the procedures in this insert, contact the technical service team at Salimetrics or your local sales representative.

Storage

All components of this kit are stable at 2 - 8°C until the kit's expiration date.

Precision

The intra-assay precision was determined from the mean of 12 replicates each.

The inter-assay precision was determined from the mean of average duplicates for 8 separate runs.

Sensitivity

The lower limit of sensitivity was determined by interpolating the mean optical density minus 2 SDs of 10 sets of duplicates at the 0 pg/mL level. The minimal concentration of 17OHP that can be distinguished from 0 is 3.0 pg/mL.

General Description

17OHP (17-OH Progesterone, 17-hydroxy-4-pregnene-3,20-dione) is a steroid hormone produced in the adrenal glands and the gonads. Immediate precursors are progesterone or 17-hydroxypregnenolone. In the human adrenal gland, 17OHP is metabolized to 11-deoxycortisol, which is then further converted to the main end product cortisol. Production and conversion of 17OHP are therefore essential to normal adrenal function.
17OHP also serves as a precursor to the androgens and the estrogens, with androstenedione serving as the intermediary metabolite. The enzymatic activity that converts 17OHP into androstenedione varies considerably according to species, however. In the human adrenal, testis, and ovary, 17OHP conversion to androstenedione is inefficient, and DHEA instead serves as the main precursor to androstenedione. 17OHP produced in the human gonadal tissues is therefore largely an end product that enters the circulation, and, in the absence of adrenal dysfunction, circulating 17OHP levels reflect gonadal rather than adrenal production. 17OHP levels correlate with the changes in circulating estrogen levels seen during the follicular and luteal phases of the menstrual cycle in women.
17OHP levels follow a circadian rhythm similar to that of cortisol, with highest values in the morning and a nadir in the evening. 17OHP levels in humans are high at birth and drop rapidly over the first few days of life; they continue to decline more slowly over the first year. Levels remain low until they rise again during puberty.
To ensure the most accurate results, this salivary immunoassay is designed using a matrix that matches saliva. The level of 17OHP in saliva (pg/mL) is significantly lower than levels in the general circulation (ng/mL). The standard curve range is sensitive enough to capture individual differences in the 17OHP levels expected in saliva. The current protocol uses only 50 μL of saliva per test. No separation or extractions are necessary.

Citations

Have you cited DEIA-S10023 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Establishment and validation of a nomogram to predict the risk of ovarian metastasis in gastric cancer: Based on a large cohort

WORLD JOURNAL OF CLINICAL CASES

Authors: Li, Shao-Qing; Zhang, Ke-Cheng; Li, Ji-Yang; Liang, Wen-Quan; Gao, Yun-He; Qiao, Zhi; Xi, Hong-Qing; Chen, Lin

Abstract

BACKGROUND Ovarian metastasis is a special type of distant metastasis unique to female patients with gastric cancer. The pathogenesis of ovarian metastasis is incompletely understood, and the treatment options are controversial. Few studies have predicted the risk of ovarian metastasis. It is not clear which type of gastric cancer is more likely to metastasize to the ovary. A prediction model based on risk factors is needed to improve the rate of detection and diagnosis. AIM To analyze risk factors of ovarian metastasis in female patients with gastric cancer and establish a nomogram to predict the probability of occurrence based on different clinicopathological features. METHODS A retrospective cohort of 1696 female patients with gastric cancer between January 2006 and December 2017 were included in a single center, and patients with distant metastasis other than ovary and peritoneum metastasis were excluded. Potential risk factors for ovarian metastasis were analyzed using univariate and multivariable logistic regression. Independent risk factors were chosen to construct a nomogram which received internal validation. RESULTS Ovarian metastasis occurred in 83 of 1696 female patients. Univariate analysis showed that age, Lauren type, whether the primary lesion contained signet-ring cells, vascular tumor emboli, T stage, N stage, the expression of estrogen receptor, the expression of progesterone receptor, serum carbohydrate antigen 125 and the neutrophil-to-lymphocyte ratio were risk factors for ovarian metastasis of gastric cancer (all P < 0.05). Multivariate analysis showed that age = 50 years, Lauren typing of non-intestinal, gastric cancer lesions containing signet-ring cell components, N stage > N2, positive expression of estrogen receptor, serum carbohydrate antigen 125 > 35 U/mL, and a neutrophil-to-lymphocyte ratio > 2.16 were independent risk factors (all P < 0.05). The independent risk factors were constructed into a nomogram model using R language software. The consistency index after continuous correction was 0.840 [95% confidence interval: (0.774-0.906)]. After the internal self-sampling (Bootstrap) test, the calibration curve of the model was obtained with an average absolute error of 0.007. The receiver operating characteristic curve of the obtained model was drawn. The area under the curve was 0.867, the maximal Youden index was 0.613, the corresponding sensitivity was 0.794, and the specificity was 0.819. CONCLUSION The nomogram model performed well in the prediction of ovarian metastasis. Attention should be paid to the possibility of ovarian metastasis in high-risk populations during re-examination, to ensure early detection and treatment.

Early resynchronization protocols for goats: Progestogens can be used prior to an early pregnancy diagnosis without affecting corpus luteum functionality

REPRODUCTION IN DOMESTIC ANIMALS

Authors: Cosentino, Isabel Oliveira; Balaro, Mario Felipe Alvarez; Leal, Felipe Seabra Cardoso; Barbosa, Lucas de Figueiredo Cardoso; Goncalves, Fernanda Martins; Felizardo, Gabriel Feliciano; Netto, Marina Monteiro; Brandao, Felipe Zandonadi

Abstract

This study aimed to evaluate the exogenous progesterone (P4) effect on the luteal function from Day 16 to Day 21 of the oestrous cycle in inseminated goats with unknown pregnancy status. A total of 54 does passed through a short progestin-based synchronization protocol and, on Day 16 of the following oestrous cycle, 27 does received a new P4 device which was retained until Day 21. Blood samples were collected daily from all does during this period, as well as on Day 24. Pregnancy diagnoses were performed on Day 30. Serum P4 values from 26 animals (G(NPSP): Group of non-pregnant does with second sponge:n = 8; G(NPNSP): Group of non-pregnant does without second sponge:n = 6; G(PSP): Group of pregnant does with second sponge:n = 5; G(PNSP): Group of pregnant does without second sponge:n = 7) were determined by radioimmunoassay commercial kits. No P4 differences were found between groups (G(NPSP): 3.1 +/- 2.8; 1.7 +/- 1.8; 0.4 +/- 1.0; and 0.0 +/- 0.0 vs. G(NPNSP): 4.4 +/- 1.8; 3.0 +/- 2.2; 0.8 +/- 0.8; and 0.0 +/- 0.0 or G(PSP): 4.2 +/- 1.0; 3.4 +/- 0.6; 3.3 +/- 1.6; 3.2 +/- 0.9; 3.6 +/- 1.2; 3.5 +/- 1.3; 2.7 +/- 1.3 vs. G(PNSP): 4.4 +/- 1.6; 3.6 +/- 1.5; 3.7 +/- 1.5; 3.8 +/- 1.4; 3.2 +/- 1.2; 3.1 +/- 1.2; 3.6 +/- 1.1; D16, D17, D18, D19, D20, D21, D24, respectively) or for the interaction of group and time. In conclusion, a second progestogen device had no effect on luteolysis or early pregnancy in the following oestrous cycle.